{"prompt": "['Improving Physical Function in Sarcoma Survivors', 'Protocol number: eIRB# 19942', 'Version # 4.0', '16 APR 2020', 'PI: Lara Davis, MD', 'study data.', 'In the absence of a formal monitoring plan, the Investigator may work with his/her study team to', 'conduct and document internal monitoring of the study to verify protection of human', 'participants, quality of data, and/or ongoing compliance with the protocol and applicable', 'regulatory requirements.', 'If at any time Investigator noncompliance is discovered at OHSU, the Investigator shall promptly', 'either secure compliance or halt the study.', 'Independent audits will be conducted by the Knight DSMC to verify that the rights and well-', 'being of human participants are protected, that the reported trial data are accurate, that the', 'conduct of the trial is in compliance with the protocol and applicable regulatory requirements,', 'and that evidence of ongoing investigator oversightis present.', '10.3 QUALITY ASSURANCE & QUALITY CONTROL', 'The investigational site will provide direct access to all trial related source data/documents, and', 'reports for the purpose of monitoring by the monitor and/or sponsor, and auditing by the Knight', 'DSMC and/or regulatory authorities.', 'Quality assurance (QA) auditing activities will occur as detailed in the Knight DSMP. All', 'discrepancies, queries, deviations, observations, and findings will be compiled into a final audit', 'report along with a Corrective and Preventative Action Plan.', 'The Sponsor-investigator, or study monitor, will verify that the clinical trial is conducted and data', 'are generated, documented (recorded), and reported in compliance with the protocol, GCP, and', 'the applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good', 'Manufacturing Practices (GMP)).', '11. DAT. A HANDLING AND MANAGEMENT RESPONSIBILITIES', '11.1', 'SOURCE DATA/DOCUMENTS', 'The Investigator is responsible for ensuring the accuracy, completeness, legibility, and', 'timeliness of the data reported. All source documents should be completed in a neat, legible', 'manner to ensure accurate interpretation of data. The Investigator will maintain adequate case', 'histories of study participants, including accurate case report forms (CRFs), and source', 'documentation.', '11.2', 'PARTICIPANT & DATA CONFIDENTIALITY', 'The information obtained during the conduct of this clinical study is confidential, and unless', 'otherwise noted, disclosure to third parties is prohibited. Information contained within this study', 'will be maintained in accordance with applicable laws protecting participant privacy, including', 'the provisions of the Health Insurance Portability and Accountability Act (HIPAA).', 'Participant confidentiality is strictly held in trust by the participating Investigator(s) and study', 'team. This confidentiality is extended to cover testing of biological samples and genetic tests in', 'addition to the clinical information relating to participants. Therefore, the study protocol,', '34']['Improving Physical Function in Sarcoma Survivors', 'Protocol number: eIRB# 19942', 'Version # 4.0', '16 APR 2020', 'PI: Lara Davis, MD', 'documentation, data, and all other information generated will be held in strict confidence. No', 'information concerning the study or the data will be released to any unauthorized third party', 'without prior written approval of the sponsor.', 'Authorized representatives of the sponsor, representatives of the IRB or manufacturer supplying', 'study product may inspect all documents and records required to be maintained by the', 'Investigator, including but not limited to, medical records (office, clinic, or hospital) and', 'pharmacy records for the participants in this study. The clinical study site will permit access to', 'such records.', \"The study participant's contact information will be securely stored at each clinical site for internal\", 'use during the study. At the end of the study, all records will continue to be kept in a secure', 'location for as long a period as dictated by local IRB and institutional regulations. Study', 'participant research data, which is for purposes of statistical analysis and scientific reporting,', \"will be transmitted to and stored within the Knight Cancer Institute per OHSU's Information\", 'Security Directives. Individual participants and their research data will be identified by a unique', 'study identification number. The study data entry and study management systems used by', 'clinical sites and by Knight Cancer Institute research staff will be secured and password', \"protected per OHSU's Information Security Directives. At the end of the study, all study\", 'databases will be de-identified and archived within the Knight Cancer Institute.', '11.3', 'DATA COLLECTION & STORAGE: PRIVACY, CONFIDENTIALITY & SECURITY', 'Data collection is the responsibility of the clinical trial staff at the site under the supervision of', 'the site Investigator. The Investigator is responsible for ensuring the accuracy, completeness,', 'legibility, and timeliness of the data reported. Standard institutional practices will be followed as', \"described in the OHSU's Information Security Directives to maintain the confidentiality and\", 'security of data collected in this study. Study staff will be trained with regard to these', 'procedures.', 'Loss of participant confidentiality is a risk of participation. Efforts will be made to keep study', \"participant identities confidential except as required by law. Participants' samples will be\", 'identified by code only. Specifically, each consenting participant will be assigned a unique', 'coded identifier consisting of numbers. This identifier will be associated with the participant', 'throughout the duration of their participation in the trial. The coded identifier will also be used to', 'identify any participant specific samples.', 'Basic accrual tracking information (demographic, consent, visit information) will be captured in', \"OHSU's electronic clinical information research system (eCRIS), hosted on OHSU secure\", \"servers and managed by OHSU's information technology group at their data center in downtown\", 'Portland, Oregon. Any additional printed documents containing participant identifiers, such as', 'those from the medical record to confirm eligibility, will be filed in binders and kept in a locked,', 'secure location.', 'Study outcome data will be captured in electronic case report forms (eCRFs) using an electronic', 'data capture (EDC), REDCap, system on OHSU secure servers, which facilitates information', 'being stored in a unified format and location. To further preserve confidentiality, PHI in the EDC', 'system will be limited to just birth date and visit dates. The web-accessible EDC system is', 'password protected and encrypted with role-based security, and administered by designated', 'informatics staff within OHSU or Knight Cancer Institute. All users of the database are assigned', '35']\n\n###\n\n", "completion": "END"}